EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Evolus Inc (EOLS) fair value: what the stock is really worth

We calculate from audited financials what Evolus Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jun 23, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US30052C1071

EI Evolus Inc logo Thin data Jun 23, 2026

Evolus Inc

EOLS · US

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value $15.79 · Strongly undervalued (+97%)
!Quality 38/100
!Mixed Growth (revenue 5y +39.4 %/yr)
!Loss-making · -14.4% net margin (TTM)
!Negative equity (buybacks among others) · negative free cash flow
!Mixed vs. peers (3/7)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Evolus Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$17.49 $3.94 Fair Value $15.79 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.

How to read this chart

60‑month range $3.94 – $17.49 · fair‑value band $11.85 – $19.74 · the $8.00 price screens below the $15.79 fair value. Dashed = 300-day average. As of Jun 23, 2026.

Follow Evolus in your weekly email

Every Wednesday you see whether Evolus is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.

Show more

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Stock analysis

Evolus Inc (EOLS) currently trades at $8.00, while our model-based Fair Value estimate is $15.79, implying the stock looks roughly 49.3% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 3 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $11.85 (bear) to $19.74 (bull), the price of $8.00 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Evolus Inc reported revenue of $297M in FY2025 versus $99.7M in FY2021, a compound +31.4%/yr. Reported net income was −$51.6M in FY2025.

Key figures

Market cap $516M · P/S ratio 1.45 · EPS (TTM) $−0.6600 · Net margin −17.4% · Return on equity −18,730% · Return on assets (EBIT) −22.3% · Operating margin −9.4% · Revenue (TTM) $302M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 14% below its 52-week high and 103% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 97%, EOLS screens cheaper than that median.

Notify me when EOLS reaches fair value

Put EOLS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 38/100

Of which business quality 39 · Market factors (momentum, volatility) 59

Profitability 50
Margins and returns on capital today
Quality Growth 55
Are margins and returns improving?
Cashflow 7
Earnings quality: real cash, not paper profit
Fin. Strength 27
Balance sheet, leverage, solvency risk
Investment 86
Disciplined investing over empire-building
Low Volatility 18
Calm price path (market factor)
Momentum 81
Price trend over the last 3–12 months (market factor)
52W Momentum 69
Distance to the 52-week high (market factor)
Net Issuance 37
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+11.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−270.7% (2020) → −12.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch EOLS, get fair value alerts →

Compare Evolus Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 631 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside +97% · Top 25%
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −9% · Bottom 25%
Net margin (TTM) −14% · Bottom 25%
Operating margin (TTM) −9% · Bottom 25%
Growth and dividend
Revenue growth 7% · Above median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 1.71× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 15
FUTURE (revenue growth)34 · sector 20
PAST (return on equity)0 · sector 27
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.15 €108.70 −18%
Takeda Pharmaceutical Company TAK $18.95 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.52 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $72.86 $108.48 +49%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Evolus Inc · Fair Value
$15.79 +49%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Evolus Inc Fair Value". https://www.fairvalue-calculator.com/stock/EOLS

Frequently asked questions

Is Evolus Inc (EOLS) overvalued or undervalued?
As of Jun 23, 2026, our model estimates a fair value of $15.79 versus a price of $8.00, about +97% upside (undervalued).
What is the fair value of EOLS?
Our model-based fair value for Evolus Inc is $15.79 (as of Jun 23, 2026), built from audited fundamentals. The current price: $8.00.
What is the quality score of EOLS?
Evolus Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Evolus Inc (EOLS)?
Our model-based price target is the fair value of $15.79 (as of Jun 23, 2026) from 3 valuation models. Cautious scenario $11.85, optimistic scenario $19.74. It is a calculation from audited fundamentals, not an analyst target.
What is the Evolus Inc stock forecast for 2026?
Our models put fair value at $15.79, about +97% upside versus a price of $8.00 (undervalued). Cautious scenario $11.85, optimistic scenario $19.74. The calculation is refreshed regularly with new filings.
What is the revenue of Evolus Inc (EOLS)?
Evolus Inc reported trailing-twelve-month revenue of about $302M (latest available figure, as of Jun 23, 2026).
What is the intrinsic value of Evolus Inc (EOLS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Evolus Inc it is $15.79 per share (as of Jun 23, 2026), against a price of $8.00. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Evolus Inc stock overvalued or undervalued in 2026?
As of Jun 23, 2026, EOLS trades below its calculated fair value: price $8.00, fair value $15.79, a gap of about +97% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EOLS?
No. The price is what the market pays today ($8.00); the fair value is what the company's own numbers justify ($15.79). For Evolus Inc the two are $7.79 per share apart. That gap is exactly why we show both numbers side by side.
How much is Evolus Inc worth?
The market values Evolus Inc at about $516M (market capitalisation, as of Jun 23, 2026). Per share that is $8.00; our models calculate a fair value of $15.79 per share.
What do the bullish and bearish scenarios say about EOLS?
Our models span a range for Evolus Inc: cautious scenario $11.85, base $15.79, optimistic $19.74 per share (as of Jun 23, 2026, price $8.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Evolus Inc (EOLS)?
Balance-sheet figures for Evolus Inc (as of Jun 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is EOLS from its 52-week high?
Evolus Inc trades at $8.00, about 14% below its 52-week high of $9.30 and 103% above the low of $3.94 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $15.79 is for.
Which stocks are comparable to Evolus Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Evolus Inc stock attractive at the current price?
The data as of Jun 23, 2026: price $8.00, calculated fair value $15.79 (+97%), Quality Score 38/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EOLS calculated?
We run Evolus Inc through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $15.79, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Evolus Inc currently trades 97 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Evolus Inc (EOLS)?
The closing price on Sep 23, 2026 was $8.00. Our model-based fair value is $15.79, about +97% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Evolus Inc right now?
The large discount to fair value meets weak quality (38/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($11.85). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Evolus Inc

How large is the market capitalisation of Evolus Inc (EOLS)?
The market capitalisation of Evolus Inc is $516M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Evolus Inc (EOLS)?
The price-to-sales ratio of Evolus Inc is 1.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Evolus Inc (EOLS)?
Earnings per share at Evolus Inc are $−0.6600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Evolus Inc (EOLS)?
The net margin of Evolus Inc is −17.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Evolus Inc (EOLS)?
The return on equity (ROE) of Evolus Inc is −18,730% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Evolus Inc (EOLS)?
On an EBIT basis the return on assets of Evolus Inc is −22.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Evolus Inc (EOLS)?
The operating margin of Evolus Inc is −9.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Evolus Inc (EOLS)?
Revenue at Evolus Inc is growing +6.7% versus a year earlier (3y avg +26.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Evolus Inc (EOLS) generate?
The free cash flow of Evolus Inc is −$45.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Evolus Inc (EOLS) carry?
The net debt of Evolus Inc is $101M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Evolus Inc in the live analysis

One click puts Evolus Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.